New Zealand markets open in 9 hours 52 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.4800-0.0600 (-2.36%)
At close: 04:00PM EST
2.4800 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.5400
Open2.6000
Bid2.4800 x 1400
Ask2.7000 x 800
Day's range2.4500 - 2.6800
52-week range2.2500 - 28.4900
Volume322,578
Avg. volume4,046,740
Market cap58.188M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.8090
Earnings date21 Mar 2022 - 25 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.67
  • Business Wire

    Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

    SAN FRANCISCO, January 24, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congen

  • Business Wire

    Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer

    SAN FRANCISCO, January 05, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer.

  • Zacks

    5 Beaten-Down Biotech Bets to Bounce Back in 2022

    Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.